...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >VEGF and IL-18 in induced sputum of lung cancer patients.
【24h】

VEGF and IL-18 in induced sputum of lung cancer patients.

机译：肺癌患者诱导痰中的VEGF和IL-18。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cytokines are key players in the biological processes of malignant tumors and special interest has been focused on cytokines exerting tumor and anti-tumor properties, such as vascular endothelial growth factor (VEGF) and Interleukin-18 (IL-18). Aim of this study was to assess IL-18 and VEGF levels in induced sputum of lung cancer patients at diagnosis, and assess their possible association with the histological type of cancer, the stage and the overall patient survival. Seventy six patients with a diagnosis of lung cancer were recruited and were followed up for 48months. Thirteen healthy smokers and 16 healthy non-smokers were used as control groups. VEGF and IL-18 were measured by ELISA in sputum supernatants at the time of diagnosis. Lung cancer patients had significantly higher baseline IL-18 and VEGF levels compared to healthy controls (p<0.001). No difference was found in IL-18 and VEGF levels between the various stages in non-small cell lung cancer (NSCLC) and between limited and extended small cell lung cancer (SCLC). However, the ratio of VEGF/IL-18 was significantly higher in NSCLC compared to SCLC patients (p=0.018). In extended SCLC overall survival was inversely associated with baseline sputum VEGF levels (p=0.034) and estimated mortality risk was 1.14 (95% CI 1.006-1.283) for an increase of 100pg/ml in VEGF levels. Such association was not found regarding baseline IL-18 levels. VEGF levels in induced sputum may have a prognostic role in the survival of SCLC. The ratio VEGF/IL-18 in induced sputum differs between NSCLC and SCLC, indicating differences in angiogenesis mechanisms and/or immunological response in these two major histological types of lung cancer.
机译：细胞因子是恶性肿瘤生物学过程中的关键角色，特别关注的是发挥肿瘤和抗肿瘤特性的细胞因子，例如血管内皮生长因子（VEGF）和白介素18（IL-18）。这项研究的目的是评估诊断时肺癌患者痰中IL-18和VEGF的水平，并评估其与癌症的组织学类型，分期和患者总体生存率的可能关系。招募了76名诊断为肺癌的患者，并进行了48个月的随访。十三名健康吸烟者和十六名健康非吸烟者被用作对照组。诊断时，通过ELISA测定痰上清中的VEGF和IL-18。与健康对照组相比，肺癌患者的基线IL-18和VEGF水平明显升高（p <0.001）。在非小细胞肺癌（NSCLC）的不同阶段之间以及有限和扩展小细胞肺癌（SCLC）之间的IL-18和VEGF水平均未发现差异。然而，与SCLC患者相比，NSCLC中VEGF / IL-18的比例明显更高（p = 0.018）。在延长的SCLC中，总生存与痰标本中的VEGF水平呈负相关（p = 0.034），估计的死亡风险为1.14（95％CI 1.006-1.283），VEGF水平升高100pg / ml。关于基线IL-18水平未发现这种关联。诱导痰中的VEGF水平可能对SCLC的存活具有预后作用。在NSCLC和SCLC之间，诱导痰中VEGF / IL-18的比例有所不同，表明这两种主要的组织学类型的肺癌的血管生成机制和/或免疫应答均存在差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号